TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8342319
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza (TI) vaccines
Study: 29661635
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving intermittent preventive treatment (IPT) with dihydroartemisinin-piperaquine (DP)
Study: 24702445
Drug: o/w formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: o/w formulation containing licochalcone A, decanediol, menthoxypropanediol and ω‐6‐fatty acids (emollient arm)
Study: 23984793
Drug: Exenatide +
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide + Metformin
Study: 22512264
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Metformin
Study: 20530557
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and home exercise programme
Study: 20530557
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (inactive ultrasound therapy and inert gel)
Study: 18206891
Drug: Hcy-lowering agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hcy-lowering agents (folate 1000 mcg, vitamin B12 400 mcg, vitamin B6 10 mg)
Study: 15531493
Drug: 10 x
Normalized name: PAD,ABDOMINAL 10 X 12 NONSTERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 x 250 mg T enanthate (TE) im every 3 wk (n = 20)
Study: 15531493
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1000 mg TU im every 6 wk (loading dose) followed by 1 x 1000 mg after an additional 9 wk (n = 20)
Study: 15531493
Drug: 8 x
Normalized name: Mepilex AG 8 x 8"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 x 1000 mg TU every 12 wk in former TU patients (n = 20)
Study: 15531493
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1000 mg TU every 8 wk plus 6 x 1000 mg every 12 wk in former TE patients (n = 16)
Study: 11570643
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no DEX treatment)
Study: 18815989
Drug: Group-administered interventions
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-administered interventions
Study: 16946607
Drug: Chewing gums
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gums (1.3 g xylitol)
Study: 16946607
Drug: Sucking tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucking tablets (0.8 g xylitol)
Study: 16946607
Drug: Candy tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candy tablets (1.1 g xylitol)
Study: 16946607
Drug: Toothpaste (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste (0.1 g xylitol)
Study: 16946607
Drug: Rinse (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse (1.0 g xylitol)
Study: 16946607
Drug: LX rinse
Normalized name: LX-7101
DrugBank: LX-7101 (DB16009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX rinse (2.0 g xylitol)
Study: 16946607
Drug: HX rinse
Normalized name: Penicillin HX
DrugBank: Amdinocillin (DB01163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX rinse (6.0 g xylitol)
Study: 8416021
Drug: Intranasal arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal arginine vasopressin (20 IU)
Study: 22933207
Drug: Trial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial treatment (TT)
Study: 22933207
Drug: Routine thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine thrombolytic treatment (Thrx)
Study: 22933207
Drug: Trial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial treatment (TT) subgroup (refused participation)
Study: 20424804
Drug: Supplement intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplement intervention (oral liquid nutrition supplementation)
Study: 18519918
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg qd for 14 days
Study: 18519918
Drug: carbamazepine titrated
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carbamazepine titrated to 400 mg qd for 21 days
Study: 1660530
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (28 g [1 oz] twice daily)
Study: 10328017
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ; 80 mg of TMP and 400 mg of SMZ per tablet; nine tablets taken once daily for three days; total, 27 tablets)
Study: 10328017
Drug: Tetracycline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (2 g daily for five days)
Study: 26456162
Drug: Captopril (0.5%)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (0.5%) cream
Study: 26456162
Drug: Diltiazem (2%)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (2%) cream
Study: 15896919
Drug: Clonidine challenge
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine challenge study for assessment of growth hormone release as a marker of tonic noradrenergic activation.
Study: 8923354
Drug: DAB 486IL-2
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAB 486IL-2 at 0.075 mg/kg/day
Study: 24559619
Drug: Finasteride (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (2.5 mg every 3 days for 6 months)
Study: 19911858
Drug: Prucalopride 4
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 4 mg once daily
Study: 20529205
Drug: Prucalopride 1
Normalized name: prucalopride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 1 mg once daily
Study: 20529205
Drug: Prucalopride 1
Normalized name: prucalopride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 1 mg and 4 mg once daily
Study: 20529205
Drug: Prucalopride (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (1-4 mg once daily)
Study: 18849320
Drug: Lapatinib (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,250 mg once daily on days 1‐21) plus capecitabine (1,000 mg/m2 every 12 hours on days 1‐14) every 21 days
Study: 18849320
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (1,250 mg/m2 every 12 hours on days 1‐14) every 21 days
Study: 15640411
Drug: CO2 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 with small added amounts of ioxaglate (200 mgI/mL)
Study: 14686228
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral ganciclovir therapy
Study: 10555883
Drug: CDP571 1
Normalized name: CDP571
DrugBank: Senlizumab (DB17894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 1 mg/kg
Study: 10555883
Drug: CDP571 10
Normalized name: CDP571
DrugBank: Senlizumab (DB17894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 10 mg/kg
Study: 8532768
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 1 month
Study: 1885075
Drug: 5-ASA 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA 1 g enema
Study: 1885075
Drug: 5-ASA 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA 2 g enema
Study: 1885075
Drug: 5-ASA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA 4 g enema
Study: 31621933
Drug: Edaravone (24-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (24-week treatment)
Study: 31621933
Drug: Edaravone (48-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (48-week treatment)
Study: 31621933
Drug: Placebo (24-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (24-week treatment followed by edaravone)
Study: 31621933
Drug: Edaravone (actual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (actual treatment)
Study: 30243949
Drug: Group-oriented integrative
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-oriented integrative medicine approach combining dietary intervention and mind-body therapies followed by 8 weeks of telephonic health coaching
Study: 30243949
Drug: Group-oriented integrative
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-oriented integrative medicine approach
Study: 28824193
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac suppository plus 5 mg isosorbide dinitrate sublingual tablet
Study: 28824193
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac suppository alone
Study: 16024585
Drug: Almitrine 4
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 4 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM4+NO)
Study: 16024585
Drug: Almitrine 16
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine 16 microg kg(‐1) min(‐1) and inhaled NO 10 p.p.m. (ALM16+NO)
Study: 12088576
Drug: Extemporaneously syringe-mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Study: 12088576
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of hepatitis A and B vaccine (Twinrix) and Vi polysaccharide vaccine (Typherix)
Study: 8523192
Drug: High-dose tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tyrosine supplementation (100 mg/kg body weight per day)
Study: 1950390
Drug: General intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: General intensive care treatment and monitoring with a pulmonary artery catheter
Study: 7134227
Drug: Influenza aluminium
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Influenza aluminium oxide adsorbate vaccine
Study: 7134227
Drug: Aqueous vaccine
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous vaccine
Study: 31696544
Drug: PUR1900 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR1900 (20 mg)
Study: 31696544
Drug: Oral Sporanox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Sporanox (200 mg)
Study: 31696544
Drug: PUR1900 (10-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR1900 (10-35 mg)
Study: 31668569
Drug: Non-MSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-MSC treatment (prednisone and azithromycin)
Study: 24814090
Drug: Etrolizumab 100
Normalized name: pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etrolizumab 100 mg (subcutaneous at weeks 0, 4, and 8, with placebo at week 2)
Study: 24814090
Drug: Etrolizumab 300
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 300 mg plus loading dose (420 mg at week 0, followed by 300 mg at weeks 2, 4, and 8)
Study: 24814090
Drug: Etrolizumab 100
Normalized name: pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etrolizumab 100 mg
Study: 24814090
Drug: Etrolizumab 300
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 300 mg plus loading dose
Study: 22266332
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel and placebo
Study: 22266332
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel and an aromatase inhibitor
Study: 19468278
Drug: S(+)‐ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (2 mg/kg/h)
Study: 17346020
Drug: Prontosan wound
Normalized name: PRONTOSAN WOUND GEL BRAUN #400560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prontosan wound irrigation and Prontosan gel
Study: 8798100
Drug: Nebivolol 2.5
Normalized name: nebivolol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 2.5 mg daily
Study: 19819787
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg daily
Study: 1474161
Drug: Scopolamine 0.2
Normalized name: scopolamine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.2 mg
Study: 1474161
Drug: Scopolamine 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.08 mg, 0.1 mg, and 0.2 mg; Promethazine 12.5 mg and 25 mg
Study: 1474161
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 1 mL)
Study: 6372084
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg suppositories
Study: 6372084
Drug: Oxyphenbutazone 250
Normalized name: oxyphenbutazone
DrugBank: Oxyphenbutazone (DB03585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyphenbutazone 250 mg suppositories
Study: 31927346
Drug: Yoga (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (12 supervised weekly sessions)
Study: 26065866
Drug: Direct thrombus
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct thrombus imaging (DTHI) without contrast agent
Study: 19503764
Drug: N-Acetylcarnosine (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetylcarnosine (1% NAC) eye drops administered topically for 9 months
Study: 19503764
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops administered topically for 9 months
Study: 16995328
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea tincture (4 ml)
Study: 16995328
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea tablets (12 tablets)
Study: 16995328
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea (both preparations)
Study: 14972468
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) - 20-Hz square waves at a 300-microsecond pulse duration for 15 minutes twice daily for 1 month.
Study: 14972468
Drug: Extracorporeal Magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Magnetic Innervation (ExMI) - Neocontrol system, 20 minutes twice a week for 2 months, with pulse frequencies of 10 Hz and 50 Hz.
Study: 9551748
Drug: PAV (8.6+/‐3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAV (8.6+/‐3.6 cmH2O x L(‐1) and 3+/‐1.3 cmH2O x L(‐1)x s(‐1) of volume and flow assistance, EPAP: 1 cmH2O)
Study: 8068939
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-6 (rhIL-6) at doses of 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d
Study: 8068939
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-6 (rhIL-6) at doses starting from 2.5 micrograms/kg/d
Study: 8068939
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-6 (rhIL-6) at doses of 10 and 20 micrograms/kg/d
Study: 3174723
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (80 mg/daily) for 5 days
Study: 10931080
Drug: Quinagolide (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (0.075 mg/day to 0.6 mg once daily)
Study: 10931080
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg/week to 1.5 mg twice weekly)
Study: 2823841
Drug: 1500 IU
Normalized name: Vitamin E 1500 IU/30 GM Topical application Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 IU low molecular weight heparin (LMWH)
Study: 2823841
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU low molecular weight heparin (LMWH)
Study: 2823841
Drug: 2500 IU
Normalized name: Vitamin A/Vitamin D 2500 IU-270 IU Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 IU low molecular weight heparin (LMWH)
Study: 31929100
Drug: OMT (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT (optimal medical therapy)
Study: 30288474
Drug: Maralixibat 70
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat 70 µg/kg/day
Study: 30288474
Drug: Maralixibat 140
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat 140 µg/kg/day
Study: 30288474
Drug: Maralixibat 280
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat 280 µg/kg/day
Study: 30288474
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of maralixibat combined
Study: 30288474
Drug: Maralixibat (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat (any dose)
Study: 23766611
Drug: Topical Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Steroids
Study: 17595435
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acids at 1.5 g/kg/d for >24 hours
Study: 17595435
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acids at 3 g/kg/d for short (5 hours), extended (24 hours), or prolonged (3-5 days) duration
Study: 8694986
Drug: Oral-B 35
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B 35 toothbrush (Control)
Study: 2038927
Drug: Saline (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.05, 0.1, 0.2, 0.3 and 0.5 ml)
Study: 2038927
Drug: Needle insertions
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle insertions using different needle sizes (20 G, 23 G and 30 G)
Study: 2038927
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% (0.1 ml, 30 G needle)
Study: 2038927
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% (0.1 ml, 30 G needle)
Study: 2038927
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (0.1 ml, 30 G needle)
Study: 2038927
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% (0.1 ml, 30 G needle)
Study: 152937
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluids (control group)
Study: 21949036
Drug: Sanofi‐Aventis branded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanofi‐Aventis branded enoxaparin (SAe) 40 mg subcutaneously once daily for 7 to 10 days
Study: 21949036
Drug: eurofarma‐enoxaparin (Ee)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eurofarma‐enoxaparin (Ee) 40 mg subcutaneously once daily for 7 to 10 days
Study: 7473485
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) after fasting
Study: 7473485
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) after feeding
Study: 7473485
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate (MTX)
Study: 7023520
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 2 mg kg‐1 plus atropine 0.03 mg kg‐1
Study: 7023520
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 4 mg kg‐1 plus atropine 0.03 mg kg‐1
Study: 7023520
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 4 mg kg‐1
Study: 7023520
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 2 mg kg‐1
Study: 7023520
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 2 mg kg‐1 and 4 mg kg‐1
Study: 31894037
Drug: Kuntai capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai capsules (4 capsules per time, 3 times a day)
Study: 31894037
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium enteric‐coated tablets (25mg, 3 times a day)
Study: 26738329
Drug: Shugan Yiyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Yiyang Capsules combined with sertraline hydrochloride 50 mg qd
Study: 26738329
Drug: sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sertraline hydrochloride 50 mg qd
Study: 23361162
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg alcohol (low dose)
Study: 23361162
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg alcohol (high dose)
Study: 22506537
Drug: Cinnarizine 20
Normalized name: cinnarizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 20 mg/dimenhydrinate 40 mg (fixed combination)
Study: 21401214
Drug: Cinnarizine 20
Normalized name: cinnarizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 20 mg (monotherapy)